144 related articles for article (PubMed ID: 37400146)
21. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.
Serizawa M; Koh Y; Kenmotsu H; Isaka M; Murakami H; Akamatsu H; Mori K; Abe M; Hayashi I; Taira T; Maniwa T; Takahashi T; Endo M; Nakajima T; Ohde Y; Yamamoto N
Cancer; 2014 May; 120(10):1471-81. PubMed ID: 24700479
[TBL] [Abstract][Full Text] [Related]
22. Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
Liu Y; Liu T; Li N; Wang T; Pu Y; Lin R
Lung Cancer; 2019 Mar; 129():92-94. PubMed ID: 30797499
[TBL] [Abstract][Full Text] [Related]
23. ROS1 as a possible prognostic biomarker of cervical adenocarcinoma: An exploratory analysis with next-generation sequencing.
Machida H; Matsuo K; Tanaka M; Kitatani K; Takase A; Yokoyama K; Kajiwara H; Yasaka M; Ikeda M; Yoshida H; Hirasawa T; Mikami M
Gynecol Oncol; 2023 Apr; 171():59-66. PubMed ID: 36804622
[TBL] [Abstract][Full Text] [Related]
24. A case of CD74-ROS1-positive lung adenocarcinoma diagnosed by next-generation sequencing achieved long-term survival with pemetrexed regimens.
Tanaka S; Yoshimura N; Asakawa R; Tobita S; Yaga M; Ueno K
Thorac Cancer; 2023 Sep; 14(25):2618-2621. PubMed ID: 37488715
[TBL] [Abstract][Full Text] [Related]
25. Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma.
Kim JH; Yoon S; Lee DH; Jang SJ; Chun SM; Kim SW
Cancer Med; 2021 May; 10(10):3197-3204. PubMed ID: 33960703
[TBL] [Abstract][Full Text] [Related]
26. Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples in Lung Cancer.
Xie F; Zheng X; Mao X; Zhao R; Ye J; Zhang Y; Sun J
Ann Thorac Surg; 2019 Jul; 108(1):219-226. PubMed ID: 30885850
[TBL] [Abstract][Full Text] [Related]
27. Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.
Lamberti G; Andrini E; Sisi M; Rizzo A; Parisi C; Di Federico A; Gelsomino F; Ardizzoni A
Crit Rev Oncol Hematol; 2020 Dec; 156():103119. PubMed ID: 33053439
[TBL] [Abstract][Full Text] [Related]
28. High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma.
Xu Y; Chang H; Wu L; Zhang X; Zhang L; Zhang J; Li Y; Shen L; Zhu X; Zhou X; Bai Q
Exp Mol Pathol; 2020 Dec; 117():104548. PubMed ID: 32979347
[TBL] [Abstract][Full Text] [Related]
29. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
[TBL] [Abstract][Full Text] [Related]
30. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
31. Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma.
Zhu J; Wang W; Xiong Y; Xu S; Chen J; Wen M; Zhao Y; Lei J; Jiang T
Cancer Med; 2023 Mar; 12(5):5545-5557. PubMed ID: 36325966
[TBL] [Abstract][Full Text] [Related]
32. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X
Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276
[TBL] [Abstract][Full Text] [Related]
34. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
[TBL] [Abstract][Full Text] [Related]
35. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.
Heredia D; Mas L; Cardona AF; Oyervides V; Motta Guerrero R; Galvez-Nino M; Lara-Mejía L; Aliaga-Macha C; Carracedo C; Varela-Santoyo E; Ramos-Ramírez M; Davila-Dupont D; Martínez J; Cruz-Rico G; Remon J; Arrieta O
Lung Cancer; 2022 Dec; 174():133-140. PubMed ID: 36379126
[TBL] [Abstract][Full Text] [Related]
36. Analysis of the status of EGFR, ROS1 and MET genes in non-small cell lung adenocarcinoma.
Wang Q; Lv Y; Zhong M; Zhu F; Wei L; Shi H
J BUON; 2017; 22(4):1053-1060. PubMed ID: 28952227
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients - A single centre experience.
Dall'Olio FG; Conci N; Rossi G; Fiorentino M; De Giglio A; Grilli G; Altimari A; Gruppioni E; Filippini DM; Di Federico A; Nuvola G; Ardizzoni A
Lung Cancer; 2020 Nov; 149():5-9. PubMed ID: 32932213
[TBL] [Abstract][Full Text] [Related]
38. Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
Wang Y; Chen Z; Han X; Li J; Guo H; Shi J
Oncologist; 2021 Mar; 26(3):178-181. PubMed ID: 33000474
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
40. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.
Xia N; An J; Jiang QQ; Li M; Tan J; Hu CP
Exp Lung Res; 2013 Oct; 39(8):328-35. PubMed ID: 23919423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]